Abos cohort includes a broad range of available data for identification and validation of new biomarkers across multiple tissues

Biomarkers have advanced our knowledge on the etiology of obesity and its links with chronic diseases. They bring substantial promise in identifying effective public health strategies that pave the way towards patient stratification and precision prevention.

Abos cohort includes a broad range of available data for identification and validation of new biomarkers across multiple tissues in ABOS cohort

Our comprehensive solutions include:

  • Scientific expertise in obesity, diabetes and metabolic diseases

Identification and validation of biomarkers in ABOS cohort:

  • Customize case-control matching studies based on propensity score
  • Tailor sensitivity studies (longitudinal biomarker analysis)
  • Monitor biomarker response to weight loss surgery
  • Biomarker-based risk stratification
  • Stratification of disease progression (i.e Type 2 Diabetes, Non-Alcoholic Liver Disease…)

Biostatistical data analysis within ABOS cohort

  • Our data analysis services within ABOS cohort can be applied to biomarker identification and validation, data visualisation and interpretation
Scroll to Top